Pharmamar Comunicó Resultados de Fase I-II en Humanos Para COVID19 con Aplidin en Octubre 2020 . Trabajan las 24 Horas los 7 Días de la Semana en el Intento de Iniciar lo Antes Posible la Fase III .

Bill Gates Alerta de Que Hay Que Prepararse Para una Próxima Pandemia y Explica Cómo Hacerlo . Hay Que Duplicar las Inversiones en I + D ... Para Poder Salir Airosos de Esta y las Que Vengan . Post By Celtia .

El Millonario realiza una predicción que espera se tenga en cuenta .

Reforzar la respuesta a pandemias es un ahorro de dinero y de vidas .

Las Vacunas ARNm son un canal de desarrollo muy esperanzador .

Nevan Krogan : " Si Los Ensayos Clínicos De Fase III Con Aplidin Comenzaran Mañana , Se Podría Ver Que Este Medicamento Se Utiliza Más Ampliamente En Un Par de Meses " ... Si Los Resultados Fueran Prometedores, dijo.

 Drug Extracted From 'Sea Squirts' Fights Coronavirus Better Than Remdesivir, Study Finds .

Research Led By Team At UCSF . 

By: Derek Staahl . 

Posted at

 Jan 27, 2021 .

SAN DIEGO (KGTV) . A cancer drug based on a compound found in a rare sea creature is 30 to 100 times more powerful against the virus that causes COVID-19 than remdesivir, according to a new set of experiments reported in Science.

In lab tests in petri dishes and mice, the drug Aplidin showed the ability to significantly slow replication of the virus and reduce lung inflammation, according to a team led by scientists at the University of California San Francisco.

Aplidin is the brand name of the drug plitidepsin, a compound originally found in a rare Mediterranean sea squirt. Sea squirts cling to rocks and coral. The creatures are named for their tendency to squirt out seawater when disturbed.

The Australian Regulatory Agency approved Aplidin n 2018 for the treatment of multiple myeloma. The drug does not have authorization from the U.S. Food and Drug Administration.

“Of all the drugs that we and our collaborators have screened [for efficacy against COVID-19], this is by far the most potent,” said Dr. Nevan Krogan, the director of UCSF’s Quantitative Biosciences Institute.

Dr. Krogan and his colleagues have been testing existing drugs to see if they can be repurposed against the virus. Instead of focusing on drugs like remdesivir that target proteins in the virus itself, they have been reviewing a catalog of therapies that target proteins in human cells that the virus needs to hijack.

“The virus can’t live by itself. It can’t replicate by itself. It needs our genes and our proteins,” Dr. Krogan said.

With viral mutations making headlines around the world, there are some concerns that adaptations in the coronavirus’ spike protein might allow the virus to eventually evade therapies like monoclonal antibodies or the vaccines. That’s where this alternate strategy of targeting human proteins has a major advantage, Krogan said.

“If you target the human protein, we don't mutate nearly as fast as a virus so you don't have to worry about it getting resistance that way,” he said.

This week, Krogan and his collaborators released early research showing Aplidin was just as effective against the UK variant as it was against the original strain. The research was posted to a pre-print server, meaning it has not yet been peer-reviewed.

“What we've also shown is that different viruses target similar human proteins, so if you're going to be able to combat SARS-CoV-2, you're probably going to [combat] SARS-CoV-3,” he said.

PharmaMar, the Spanish drugmaker behind Aplidin, has completed Phase 1 and Phase 2 trials of Aplidin for use in COVID-19 patients with positive results, setting up a large-scale Phase 3 trial, Krogan said, although the start date is unclear.

“If Phase 3 clinical trials started tomorrow, one could see this drug being more widely used in a couple of months” if the results were promising, he said.

The Drug is given in lower doses to COVID-19 patients and for a shorter period than the regimen for cancer patients, reducing the potential for side effects.

Krogan said it’s the closest any drug he’s tested has gotten to becoming a real COVID-19 treatment; a treatment straight from the Mediterranean Sea.

PharmaMar . Bankinter le Sube el Precio Objetivo Base Hasta los 125 Euros al Confíar en la Aprobación de Aplidin Contra el COVID19 . El Precio Objetivo Positivo lo Sitúa en 175 y el Precio Objetivo Negativo en 90 euros .

COVID19 . PharmaMar Versus Gilead ... APLIDIN Versus Remdesivir en Ratones Humanizados . By Adolfo García Sastre el Cual Deja la Puerta Abierta a Posibles Terapias de Combinación ...

PREGUNTA : ¿ ... Una Posible Combinación Podría Provocar un Aluvión de Posibles Novios ... ? .

Genómica SAU ( PharmaMar ) , Anuncia Que ha Validado Su Kit PCR Para el Uso de Muestras Directas de Saliva . Se elimina la Necesidad del Kit de Extracción en Laboratorio , Lo Que Permite También un Ahorro de Tiempo y Costes .

 

El Análisis de COVID-19 Con el Test PCR de GENOMICA Ha Obtenido Una Sensibilidad del 100%, Que Permite Incluso Detectar Casos Asintomáticos .

APLIDIN . El Ensayo del Dr Carballo en 122 Pacientes Asintomáticos No Ingresados se Iniciará con el OK de la Aemps ... Y en 2 o 3 Semanas Podríamos Tener Ya Datos Muy Interesantes Que Podrían Situar a APLIDIN Como el Primer Gran Tratamiento AntiViral a Nivel Mundial .